Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1201-1220 of 2,251 trials

Severe Infections in ICU: Comparing Antibiotics

We are studying whether piperacillin-tazobactam or temocillin can effectively treat severe infections caused by certain bacteria in ICU patients, compared to standard carbapenem treatment. This research may help improve treatment options for critically ill patients.

ESBL-Producing Bacteria Infection>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Antisynthetase Syndrome: Cyclophosphamide vs Tacrolimus

We are comparing the effects of Cyclophosphamide and Azathioprine against Tacrolimus in patients with antisynthetase syndrome-related lung disease. The goal is to see which treatment better improves lung function and quality of life.

Interstitial Lung DiseaseConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology

Tremelimumab Injection for Early-Stage Lung Cancer

We are studying a new injection method for delivering tremelimumab to patients with early-stage non-small cell lung cancer. The goal is to evaluate its safety and how well it works in the body.

Non-small cell lung cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Recurrent Solid Tumors: OBT076 Treatment Study

We are testing the safety and effectiveness of OBT076 in patients with recurrent or metastatic CD205-positive solid tumors. This study will also explore how it works with another treatment called balstilimab.

Malignant Solid Tumor1-2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

COPD Exacerbation: New Diagnostic Strategy

We are testing a new method using advanced diagnostics to see if it can help reduce antibiotic use during severe COPD flare-ups. This study compares this approach to standard treatment to evaluate its effectiveness and safety.

Severe COPD with Ventilation Support>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPulmonology

Pancreatic Cancer: FOLFOX vs. Gemcitabine

We are comparing two chemotherapy treatments, FOLFOX and gemcitabine, for patients with advanced pancreatic cancer who cannot tolerate a stronger regimen. The goal is to see which treatment works better and is safer for these patients.

Pancreatic Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Acromegaly: Paltusotine Treatment Study

We are studying the long-term safety and effectiveness of paltusotine for people with acromegaly. This research aims to improve treatment options for managing this condition.

Acromegaly>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinology

Carcinoid Syndrome: Paltusotine Treatment Study

We are evaluating the safety and how the body processes different doses of paltusotine in people with carcinoid syndrome. This study aims to ensure the treatment is safe and well-tolerated.

Carcinoid Syndrome3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Painful Venous Malformations: Apixaban Study

We are investigating whether apixaban can help reduce pain and improve quality of life for patients with painful venous malformations. The study also looks at safety and how the medication affects blood clotting.

Venous Malformation1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Pasireotide for Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

We are studying whether pasireotide can help patients with specific cancers live longer without their disease progressing. This trial focuses on those with synovial sarcoma and desmoplastic small round cell tumor.

Locally Advanced or Metastatic Synovial SarcomaLocally Advanced or Metastatic Desmoplastic Small Round Cell Tumor>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Postoperative Pain Relief After Hip Surgery: Intrathecal Morphine Study

We are testing whether intrathecal morphine, with or without a specific nerve block, can improve pain relief after total hip arthroplasty. This study aims to find the best way to manage pain during recovery.

Total Hip Replacement Surgery1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Cardiovascular Risk Management: BIO-RISK-EVENT Study

We are testing a new approach to managing heart health in patients at high risk for heart events. The goal is to see if this intensified treatment is more effective than standard care.

Heart Attack>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Oxygen Therapy for Acute Pulmonary Embolism

We are investigating whether supplemental oxygen helps patients with intermediate-risk acute pulmonary embolism improve their health and reduce hospital stays. The study also looks at its effects on survival rates over time.

Acute Pulmonary Embolism>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyPulmonology

Dapagliflozin for Decompensated Liver Cirrhosis

We are studying whether dapagliflozin is safe and effective for patients with decompensated liver cirrhosis compared to standard treatments. The trial also looks at how it may affect quality of life and various health markers.

Decompensated Liver Cirrhosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Non-Hodgkin Lymphoma: New CAR T-Cell Therapy Study

We are comparing a new point-of-care CAR T-cell treatment to a standard commercial option for patients with relapsed or refractory Non-Hodgkin Lymphoma. The goal is to see if the new therapy can improve survival and safety outcomes.

Relapsed/Refractory Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Alpha-1 Antitrypsin Deficiency: WVE-006 Treatment

We are testing a new treatment called WVE-006 for people with Pi*ZZ Alpha-1 Antitrypsin Deficiency. The study aims to evaluate its safety and how the body responds to it.

Alpha-1 Antitrypsin Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyGastroenterologyHepatologyInternal MedicinePulmonology

Mantle Cell Lymphoma: Pirtobrutinib and Rituximab Study

We are evaluating a new treatment combining pirtobrutinib and rituximab for patients with indolent Mantle Cell Lymphoma. The study aims to determine its effectiveness and safety compared to standard therapies.

Mantle Cell Lymphoma1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Atezolizumab for Muscle-Invasive Bladder Cancer

We are studying whether atezolizumab can help patients with muscle-invasive bladder cancer who cannot have surgery after chemo-radiotherapy. The trial looks at how well it works and its impact on patients' quality of life.

Muscle-Invasive Bladder Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Colorectal Cancer: STC-1010 Immunotherapy

We are studying a new immunotherapy for patients with advanced colorectal cancer that cannot be surgically removed. The trial aims to evaluate its safety and effectiveness alongside standard treatment options.

Unresectable Locally Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Inhaled Molgramostim for Pediatric Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

We are studying the effects of inhaled molgramostim in children and teens with aPAP. The goal is to see if it is safe and effective for improving their condition.

Pulmonary Alveolar Proteinosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPediatricsPulmonology